Case Study


Fractional exhaled Nitric Oxide (FeNO) testing

Fractional exhaled Nitric Oxide (FeNO) testing
Case Study Medicine safety & optimisation Kent and MedwaySurreySussex Health and care professionals

FeNO is a non-invasive test to measure the amount of nitric oxide in an exhaled breath, a biomarker for airway inflammation. It contributes to faster, and more effective asthma diagnosis and can monitor patient response to asthma treatments.

Between April 2021 and February 2023, 51 devices were spread across Kent, Surrey and Sussex benefitting c. 4,000 patients and preventing 1,450 false positive diagnoses – an equivalent saving of £420,380 a year.

Find out more in the impact reporting.

Related news

Definition Health is an award-winning provider of personalised digital health solutions for surgery. The company’s innovative platform which includes LifeBox,...

Case Study

17 Oct 2024

More

Dr Julian Nesbitt is the founder of Dr-Julian. This case study highlights his experiences of the NHS Clinical Entrepreneur Programme and working with Health Innovation KSS.

Case StudyNews

5 Sep 2024

More

Health Innovation Kent Surrey Sussex (KSS) has published its Annual Review for 2023-24, showcasing a year of remarkable growth and...

Case StudyNews

22 Aug 2024

More

Spread and adoption The AHSN Network supports adoption of innovations identified by the Accelerated Access Collaborative and those that the...

Case Study

30 Jun 2020

More